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Abstract
Background: Patients ingesting ethylene glycol, isopropanol, methanol, and propylene glycol (’toxic alcohols’)
often present with non-specific signs and symptoms. Definitive diagnosis of toxic alcohols has traditionally been by
gas chromatography (GC), a technique not commonly performed on-site in hospital clinical laboratories. The
objectives of this retrospective study were: 1) to assess the diagnostic accuracy of the osmolal gap in screening for
toxic alcohol ingestion and 2) to determine the common reasons other than toxic alcohol ingestion for elevated
osmolal gaps.
Methods: Electronic medical records from an academic tertiary care medical center were searched to identify all
patients in the time period from January 1, 1996 to September 1, 2010 who had serum/plasma ethanol, glucose,
sodium, blood urea nitrogen, and osmolality measured simultaneously, and also all patients who had GC analysis
for toxic alcohols. Detailed chart review was performed on all patients with osmolal gap of 9 or greater.
Results: In the study period, 20,669 patients had determination of serum/plasma ethanol and osmolal gap upon
presentation to the hospitals. There were 341 patients with an osmolal gap greater than 14 (including correction
for estimated contribution of ethanol) on initial presentation to the medical center. Seventy-seven patients tested
positive by GC for one or more toxic alcohols; all had elevated anion gap or osmolal gap or both. Other than toxic
alcohols, the most common causes for an elevated osmolal gap were recent heavy ethanol consumption with
suspected alcoholic ketoacidosis, renal failure, shock, and recent administration of mannitol. Only 9 patients with
osmolal gap greater than 50 and no patients with osmolal gap greater than 100 were found to be negative for
toxic alcohols.
Conclusions: Our study concurs with other investigations that show that osmolal gap can be a useful diagnostic
test in conjunction with clinical history and physical examination.
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Background
Consumption of toxic alcohols other than ethanol con-
tinues to be a public health problem [1]. The most com-
mon toxic alcohols are ethylene glycol, isopropanol, and
methanol. All three compounds are found in products
that are easily obtained (ethylene glycol in most auto-
mobile antifreezes, isopropanol in ‘rubbing alcohol’,a n d
methanol in windshield cleaner fluid and some other
products). Ethylene glycol and methanol are particularly
dangerous in overdose, due to their metabolites that can
cause severe organ damage [1-6].
Ethylene glycol is metabolized by a series of steps to gly-
colic acids and oxalic acid, the latter with the potential to
cause severe renal injury [2-5]. Methanol is likewise meta-
bolized by a series of enzymatic reactions to formic acid, a
toxic compound that can cause blindness from permanent
injury to the optic nerve. Both ethylene glycol and metha-
nol are capable of causing marked metabolic acidosis,
mainly due to their metabolites. Following ingestion of
ethylene glycol or methanol, an osmolal gap appears first
and an anion gap appears later after conversion to acidic
metabolites [1-5]. Isopropanol is generally less toxic than
ethylene glycol or methanol, as it is primarily metabolized
to acetone [7,8]. However, in addition to the organ damage
caused by metabolites of ethylene glycol and methanol, all
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vous system (CNS) depression that in and of itself may be
life-threatening [1,4].
The definitive laboratory method for detecting and
quantitating toxic alcohols in the serum/plasma is gas
chromatography (GC) [6]. However, this technique is
labor-intensive and not available at most clinical labora-
tories associated with hospitals and medical centers, with
the exception of some larger medical center laboratories.
Consequently, this analysis is generally performed at
remote reference laboratories, often precluding a turn-
around time of 2-4 hr as recommended by a consensus
panel for optimal management of patients ingesting ethy-
lene glycol or methanol [6].
Diagnosis of toxic alcohol ingestion therefore often
relies on clinical signs and symptoms along with indirect
evidence from laboratory tests such as arterial blood gas
analysis (to detect acidosis), serum osmolality (to esti-
mate osmolal gap, OG), and common chemistry tests (to
calculate anion gap). Prompt diagnosis of toxic alcohol
poisoning can provide major benefit to patients. If diag-
nosed early enough, ethylene glycol and methanol poi-
sonings are usually treated effectively by administration
of either ethanol or fomepizole, both of which inhibit the
rate-limiting first step in the metabolism of ethylene gly-
col or methanol by alcohol dehydrogenase and thus pre-
vent the formation of toxic metabolites [2,3,9,10]. Toxic
alcohol ingestions that are not diagnosed early often
require hemodialysis to clear both the parent compounds
and metabolites, although end-organ damage may already
have occurred. Conversely, an erroneous false diagnosis
of toxic alcohol ingestion has the downside of increased
expense and potential adverse effects related to antidotal
therapy and/or hemodialysis.
The OG is determined by measuring serum osmolality
(e.g., by freezing point depression) and then using a for-
mula to calculate the osmolality contribution of the
endogenous major contributors to serum osmolality,
namely sodium, blood urea nitrogen (BUN), and glucose,
which are standard chemistry tests frequently ordered in
patients with potential toxic alcohol ingestions [11,12].
The OG is the measured osmolality minus the estimated
osmolality. There are also formulae to account for the
presence of serum ethanol (if present). There is consider-
able debate over the use of OG to diagnose toxic alcohol
ingestions, and also a plethora of formulae proposed for
estimating the contribution of sodium, BUN, glucose,
and ethanol to serum osmolality [8,11-29]. An elevated
OG (often defined as greater than a threshold between
10 and 15) suggests the presence of osmotically active
substances other than sodium, BUN, glucose, and etha-
nol. The differential diagnosis for elevated OG includes a
variety of conditions other than toxic alcohol ingestion
such as alcoholic ketoacidosis [23,30-32], mannitol
infusion [33,34], renal failure [35,36], and shock [37,38].
In some of these conditions (e.g., shock), the exact osmo-
tically active compounds are not exactly known. Alco-
holic ketoacidosis can produce a substantial osmolal gap
even in the absence of detectable plasma ethanol due to
the formation of glycerol, acetone, and the acetone meta-
bolites acetol and 1,2-propanediol [31].
An additional toxic alcohol compound that can cause an
elevated OG is propylene glycol [1,39]. Although chemi-
cally similar to ethylene glycol (and also used in some auto-
mobile antifreezes), propylene glycol is generally much less
toxic than ethylene glycol. Propylene glycol is found in a
variety of products including cosmetics, ointments, some
activated charcoal preparations, and as a diluent for intra-
venous preparations of poorly water-soluble drugs such as
diazepam, etomidate, and lorazepam. Propylene glycol toxi-
city has been described in overdoses of propylene glycol-
containing antifreeze [40]. A number of studies have
detailed propylene glycol toxicity from repeated intrave-
nous administrations of medications containing propylene
glycol as the diluent, particularly lorazepam used for
extended sedation (e.g., for patients who are intubated for
mechanical ventilation) [41-45].
In this study, we performed a retrospective analysis of
toxic alcohol and OG analyses in a timespan of nearly
15 years at a tertiary care academic medical center. The
primary objectives were to assess the diagnostic accuracy
of OG as a test for screening for toxic alcohol ingestion
and to define the common causes of elevated OG in the
absence of toxic alcohol ingestion. The study conforms
to the Standards for Reporting Diagnostic Accuracy
(STARD) statement criteria [46,47].
Methods
Setting
We conducted a retrospective analysis of electronic labora-
tory and medical records from a tertiary care academic
medical center. An important panel of laboratory tests for
this study was the ‘Ethanol Volatile Panel’ which included
serum/plasma sodium, BUN, glucose, ethanol (by enzy-
matic assay), and plasma osmolality. From this panel, the
OG was calculated.. This panel was commonly ordered for
patients presenting with clinical histories, signs, and symp-
toms consistent with toxic ingestions (e.g., altered mental
status, obtundation, suicide attempt, or possible accidental
ingestion by a child). GC analysis for toxic alcohols or gly-
cols required approval by pathology resident or clinical
chemistry laboratory director (or cross-covering patholo-
gist) and often occurred in the context of an Ethanol Vola-
tile Panel showing elevated OG (> 14) after correcting
for plasma ethanol. Initial GC analysis was typically run on
the same plasma specimen that the Ethanol Volatile Panel
was performed on unless there was insufficient specimen
to do so.
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The electronic medical record (Epic, Epic Systems Inc.,
Madison, WI, USA) was searched for the time period from
1/1/1996 to 9/1/2010 for all occurrences when the Ethanol
Volatile Panel or GC analysis for toxic alcohols was
ordered. The results of these tests along with patient age,
gender, and medical center location at time of blood draw
(e.g., emergency room, inpatient floor, outpatient clinic,
etc.) were downloaded. In the event of multiple hospital
visits by a single patient, only the first visit was included in
the analysis. The project had Institutional Review Board
approval from the University of Iowa.
Figure 1 shows the patient populations and subsets that
were subjected to more detailed analysis. Chart review was
performed on all patients with OG ≥ 9 .I nt h ec a s eo f
patients with OG > 14 on initial laboratory studies but
without any detection of toxic alcohols by GC, the chart
review was intended to identify the likely cause of the ele-
vated OG. For patients with OG ≥ 9b u t≤14, the chart
review aimed to determine whether any patients had clini-
cal history compatible with toxic alcohol ingestion
whether or not GC was performed.
Methods of Measurement
All laboratory measurements were performed in the cen-
tral Clinical Chemistry laboratory. Serum/plasma electro-
lytes, BUN, glucose, b-hydroxybutyrate, and ethanol were
determined on high volume chemistry analyzers (Roche P
modules, Roche Diagnostics, Inc., Indianapolis, IN, USA).
I na d d i t i o nt oas p e c i f i cq u a n t i t a t i v ea s s a yf o rs e r u m /
plasma b-hydroxybutyrate (Stanbio Laboratory, Boerne,
TX, USA), a semi-qualitative test using a colorimetric
assay was also available for assessment of serum and urine
ketones (Acetest
®, Bayer Diagnostics, now part of Siemens
Healthcare Diagnostics, Deerfield, IL, USA). Serum/plasma
osmolality was determined by freezing point depression
(Model 2020 osmometer, Advanced Instruments, Inc.,
Norwood, MA, USA). Serum/plasma concentrations of
ethylene glycol, propylene glycol, methanol, isopropanol,
and acetone were measured by GC (Agilent 6850 with
7683 injector, Agilent Technologies, Santa Clara, CA,
USA), which served as the gold standard (reference) tech-
nique for diagnosis of toxic alcohol ingestion. The lower
concentration limit for clinical reporting for ethanol, ethy-
lene glycol, isopropanol, methanol, and propylene glycol
was 10 mg/dL. Laboratory analyses were performed by
clinical laboratory staff as part of patient care.
OG was calculated using a formula by Khajuria and
Krahn [21]:OG = (Measured osmolality) - {2 × [Sodium] +
(1.15 * [Glucose]/18) + ([BUN]/2.8) + (1.2 * [ETOH]/4.6)}
where [Sodium] is plasma sodium concentration (in mEq/
L), [Glucose] is plasma glucose concentration (in mg/dL),
[BUN] = plasma blood urea nitrogen concentration (in
mg/dL), and [ETOH] is plasma ethanol concentration (in
mg/dL). Anion gap was equal to the plasma sodium con-
centration minus the sum of the plasma bicarbonate and
chloride concentrations (all measured in mEq/L).
Sensitivity was defined as: (number of true positives)/
(number of true positives + number of false negatives).
Specificity was defined as (number of true negatives)/
(number of true negatives + number of false positives).
Statistical analyses were carried out in EP Evaluator release
9 (Data Innovations, South Burlington, VT, USA). Graphs
were generated in Kaleidagraph version 4.0 (Synergy Soft-
ware, Reading, PA, USA).
Results
Characteristics of Study Subjects
We identified 341 patients that had OG greater than 14 on
the Ethanol Volatile Panel determined on initial presenta-
tion (Figure 1; Table 1). Of these 341 patients, 285 had
GC analysis performed, identifying 77 patients with ethy-
lene glycol, propylene glycol, methanol, and/or isopropa-
nol present in serum/plasma at concentrations of 10 mg/
dL or greater by GC (Figure 2). GC analysis was also per-
formed in 185 patients with OG of 14 or less (Figure 1;
also discussed in more detail below). These analyses iden-
tified 6 patients with ethylene glycol and 1 patient with
methanol at plasma concentrations of 10 mg/dL or greater
(Table 2). There were thus a total of 84 patients with
detectable toxic alcohols on initial laboratory studies.
The anion and osmolal gaps from the initial laboratory
studies of patients with detectable ethylene glycol, isopro-
panol, and methanol by GC are shown in Figure 3.
Laboratory data necessary to calculate anion gap were not
available for 4 patients (3 with OG > 14) with detectable
toxic alcohols; thus, these 4 patients are not included in
Figure 3 (leaving a total of 80 patients). All patients that
tested positive for ethylene glycol, isopropanol, propylene
glycol, or methanol had an elevated OG or anion gap or
both, keeping in mind there was one patient with detect-
able ethylene glycol by GC who initially presented with an
OG of 6 but did not have laboratory data sufficient to cal-
culate anion gap (Table 2).
In the 84 patients who had toxic alcohols detected by GC,
54 (64.3%) had a single toxic alcohol detected without co-
ingestion of ethanol or another toxic alcohol. Twenty-nine
patients (34.5%) had both ethanol and one toxic alcohol
detected. In patients ingesting both ethanol and either
methanol or ethylene glycol, the presence of ethanol could
inhibit the metabolism of the toxic alcohol by alcohol dehy-
drogenase and thereby limit formation of toxic metabolites.
Only one patient had two toxic alcohols detected; this was
a 52 year old male who ingested “cleaning solutions” in a
suicide attempt and for whom GC analysis detected both
i s o p r o p a n o l( 1 8m g / d L )a n dm e t h a n o l( 1 0m g / d L ) .
There were 7 patients for whom propylene glycol was
the suspected primary cause of the elevated OG, with
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to 147 mg/dL and no other toxic alcohol detected. In 6
of these 7 patients, the increased OG was entirely
explained by the presence of propylene glycol, using the
propylene glycol serum concentration (in mg/dL)
d i v i d e db y7 . 2a st h ee s t i m a t ed osmolal contribution
[39]. In one patient, there was still an OG of 15 follow-
ing correction for the estimated osmolar contribution of
Figure 1 Flow diagram illustrating the derivation of the study sample. Abbreviations: EG, ethylene glycol; GC, gas chromatography; IsOH,
isopropanol; MeOH, methanol; PG, propylene glycol.
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with propylene glycol had an anion gap of 16 or greater
on initial laboratory studies (Figure 3). Two of the seven
patients had been administered multiple doses of loraze-
pam intravenously, a formulation that contains propy-
lene glycol (up to 80% v/v) as the diluent, prior to
laboratory studies. Five patients had been administered
activated charcoal preparations containing propylene
glycol at an outside hospital prior to transfer; none of
these five patients had a documented history of being
administered any medications containing propylene gly-
col as the diluent prior to the blood draw used for OG
and propylene glycol determinations.
Causes of elevated OG other than toxic alcohols
(“unexplained osmolal gaps”)
Through detailed chart review we attempted to assign the
most likely primary cause for the 264 patients who had
elevated OG (> 14) without detection of toxic alcohols on
initial laboratory studies (Figure 2). The most common
suspected causes of elevated OG in the 264 patients were
ethanol-related (including alcoholic ketoacidosis) (n = 72,
27.2%), renal failure (n = 43, 16.3%), diabetic ketoacidosis
(n = 33, 12.5%), shock (n = 32, 12.1%), and therapeutic
infusion of mannitol (n = 15, 5.7%). In 69 patients (26.1%),
none of the well-established causes of elevated OG were
found (classified in category of “Other” in Figure 2).
For the 72 patients classified in the “ethanol-related”
category, all had recent history of binge drinking (with
risk of alcoholic ketoacidosis) and an absence of clinical
suspicion for toxic alcohol ingestions. Fifty-three of
these 72 patients had detectable serum ethanol but still
showed elevated OG (> 14) after correction for the esti-
mated osmolal contribution of ethanol. Alcoholic ketoa-
cidosis is characterized by high serum ketone levels and
elevated anion gap [1,48,49], typically in the setting of
recent binge drinking with limited nutritional intake.
However, diagnosis of alcoholic ketoacidosis is some-
times only inferred because laboratory analyses such as
serum ketones may not be obtained. Even for patients
who clearly have the characteristics of alcohol ketoaci-
dosis, the diagnosis assigned to the patient in the medi-
cal record may often not be alcoholic ketoacidosis but a
more general diagnosis such as ethanol withdrawal or
intoxication.
Table 1 Demographics of patient populations
N (males/females) Average age ± SD Age range
OG > 14 341 (229/112) 43.2 ± 16.3 0.9 - 89.7
No toxic alcohol detected 264 (192/72) 42.5 ± 15.8 1.8 - 89.7
Ethanol-related 72 (52/20) 46.6 ± 14.3 14.6 - 84.9
Renal failure 43 (30/13) 48.0 ± 14.0 15.4 - 89.7
Shock 32 (18/14) 43.1 ± 18.7 14.4 - 83.8
Diabetic ketoacidosis 33 (25/8) 40.9 ± 14.2 14.2 - 69.9
Mannitol 15 (10/5) 37.9 ± 22.3 1.8 - 80.4
Other 69 (47/22) 35.7 ± 13.2 15.7 - 62.8
Toxic alcohol detected 77 (47/30) 35.5 ± 16.5 1.4 - 72.1
Ethylene glycol 37 (25/12) 35.7 ± 14.1 19.0 - 72.1
Isopropanol 19 (8/11) 30.5 ± 21.5 1.4 - 64.6
Methanol 14 (11/3) 42.3 ± 13.7 20.2 - 71.4
Propylene glycol 7 (3/4) 41.0 ± 9.6 25.6 - 54.5
Figure 2 Causes of elevated osmolal gaps. For the 341 patients
who presented with elevated osmolal gap (OG) > 14 on initial
laboratory studies on presentation to the medical center, the
suspected primary cause was determined from analysis of toxic
alcohols by gas chromatography and by chart review. The black
bars indicate number of patients where toxic alcohol ingestion was
the likely primary cause of the elevated OG. The red bars are
suspected primary causes of elevated OG in the absence of toxic
alcohol ingestions.
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pected to be related to ethanol, a breakdown of the
laboratory studies performed in the “ethanol-related”
group is included in Additional File 1. Forty-four of the
72 patients had serum ketones above upper limit of refer-
ence range and/or positive urine ketones. An additional
three patients had elevated anion gap (16 or greater) but
no laboratory analysis of ketones. Thus, 47 patients had
some laboratory characteristic of alcoholic ketoacidosis.
For the patients that had elevated OG due to a cause
other than ingestion of toxic alcohols, 12.2% had an OG
greater than 30. Only 3.2% of these patients had OG
greater than 50, and none had OG greater than 100. In
contrast, for patients ingesting toxic alcohols, 48.7% had
OG greater than 30 on initial laboratory work-up and
19.7% had OG greater than 50. All cases where OG was
greater than 80 in the absence of toxic alcohols were
patients with a history of heavy recent ethanol use and
possible alcoholic ketoacidosis. The highest OG values in
patients without history of ethanol or toxic alcohol use
were 60 (42 year old male given mannitol for increased
intracranial pressure approximately one hour prior to
blood draw) and 51 (39 year old female with fulminant
liver failure due to massive acetaminophen overdose two
days prior to admission).
For the 72 cases where recent heavy ethanol use was the
suspected main cause of the elevated OG due to alcoholic
ketoacidosis, 19 of the patients had no detectable plasma
ethanol at time of presentation to the hospital but did
have history of recent heavy consumption of ethanol and
were admitted to the hospital for management of ethanol
withdrawal symptoms. Overall, 63 of the 72 patients
whose elevated OG was suspected to be due to recent
heavy ethanol use (in the absence of toxic alcohols) had
OG values between 14 and 30. For the 7 patients with
OGs greater than 30 but no toxic alcohols detected, five
had detectable serum ethanol (ranging from 115 to 313
mg/dL). Of the 15 cases where mannitol was the suspected
cause of elevated OG, 14 had OG of 33 or less.
Toxic alcohol ingestions presenting without elevated OG
We found 7 instances where a patient had OG of 14 or
less on initial laboratory analysis had GC analysis detect
Table 2 Summary of toxic alcohol ingestions without elevated osmolal gap
Age Gender Alcohol and glycol serum
concentration
Clinical history Anion gap Osmolal
gap
2 M Methanol 12 mg/dL Ingestion of small amount of windshield fluid, brought quickly to
emergency room
16 -5
19 F Ethylene glycol 18 mg/dL Intentional ingestion of ~4 ounces of antifreeze 12 hours prior to
presentation
28 2
24 F Ethylene glycol 89 mg/dL Intentional ingestion of unknown amount of antifreeze unknown time
before presentation
27 5
32 M Ethylene glycol 44 mg/dL
Ethanol 113 mg/dL
Accidental ingestion of antifreeze 45 mins prior to emergency room
visit
Not
determined
6
39 F Ethylene glycol 30 mg/dL
Ethanol 83 mg/dL
Intentional ingestion of 8 ounces of antifreeze 6 hours prior to
presentation
15 7
40 M Ethylene glycol 27 mg/dL
Ethanol 202 mg/dL
Intentional ingestion of 4-5 “mouthfuls” of antifreeze unknown time
before presentation
17 7
44 F Ethylene glycol 32 mg/dL
Ethanol 270 mg/dL
Intentional ingestion of 1 cup of antifreeze 1 hour prior to
presentation
15 -1
Figure 3 Osmolal and anion gaps for patients who had ingested
toxic alcohols. For patients who had ethylene glycol, isopropanol, or
methanol detected by gas chromatography analysis, the osmolal gap
and anion gap on initial laboratory studies were plotted. This plot
includes a total of 73 patients. Eleven patients with toxic alcohols
detected by GC were not included due to lack of laboratory data
necessary to calculate anion gap. The data is sorted by the primary
ingestion. A single case of co-ingestion of isopropanol and methanol
is classified with the isopropanol group as that compound was
detected in higher amount in serum for that patient. Two fatal cases
each for ethylene glycol and methanol (total of 4 patients) are
designated by an asterisk (*) next to the datapoint.
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Six of 7 of these patients were positive for ethylene gly-
col, with clinical histories documenting varying amounts
of ethylene glycol ingestions ("4 oz”, “8o z ”, “1c u p ”,
“4-5 mouthfuls”, “accidental” ingestion while trying to
siphon antifreeze by mouth from radiator, and an
unknown quantity in one case). One patient was a 28
month old toddler that drank an unknown quantity of
windshield fluid containing methanol and was brought
to emergency department within 10 minutes of inges-
tion. This child had an anion gap of 16. Six of 7 patients
had anion gaps of 15 or greater. Laboratory values
needed to determine anion gap were not ordered for
one patient.
Diagnostic performance of OG
We additionally performed chart review for 510 patients
who had OG between 9 and 14 on their initial laboratory
studies. Within this group, 39 patients had GC analysis; all
were negative for presence of toxic alcohols by GC or for
any clinical history compatible with toxic alcohol ingestion.
Using data from all patients who had OG of 9 or greater
on initial laboratory studies (total n = 851), Figure 4 shows
plots of sensitivity and specificity for different OG cutoffs.
At a cutoff of 20, OG has a sensitivity of 0.82 (95% confi-
dence interval, CI, 0.71-0.89) and specificity of 0.85 (95%
CI, 0.82-0.87). At an OG cutoff of 30, the sensitivity is only
0.49 (95% CI, 0.38-0.60) with a specificity of 0.95 (0.94-
0.97). Figure 5 shows a Gerhardt plotting the number of
patients who either were shown to have ingested toxic
alcohols by GC (above y = 0 horizontal line) or did not
show toxic alcohol ingestions by GC and/or clinical chart
review (below y = 0 horizontal line).
Discussion
This study demonstrates that the OG has a sensitivity of
0.82 and a specificity of 0.85 at a cutoff of 20 for diagnos-
ing toxic alcohol ingestion. These findings are similar to
those of another recent study [22]. The most common
suspected reasons for elevated OG in the absence of toxic
alcohol ingestion (in descending order of frequency) were
suspected alcoholic ketoacidosis, renal failure, shock, dia-
betic ketoacidosis, and recent administration of mannitol.
When the elevated OG was due to something other than
toxic alcohol ingestion, the gap was typically less than 30.
For the 264 patients that had elevated OG due to a cause
other than ingestion of toxic alcohols, only 12.2% had an
OG greater than 30. Exceptions included patients with
alcoholic ketoacidosis and recent mannitol infusion, which
can present with markedly elevated OG depending on tim-
ing of laboratory analysis. In our study, all patients that
had toxic alcohols detected by GC had an osmolal gap
and/or anion gap.
Estimation of the contribution of ethanol to OG is a
complicated and controversial subject with multiple for-
mulae proposed [18,26-28,50] One challenge is that the
compounds formed in alcoholic ketoacidosis (e.g., glycerol,
acetone, acetal, and 1,2-propanediol) may contribute to
osmolality but are not directly measured by routine clini-
cal laboratory testing [23,30-32]. In our study, 19 patients
had elevated OG that by clinical history was most likely
due to recent heavy ethanol ingestion but with serum
ethanol less than 10 mg/dL.
Our study was able to detect cases of elevated OG possi-
bly due to administration of activated charcoal. In the Uni-
ted States, there are multiple formulations of activated
charcoal, some of which contain propylene glycol as the
excipient. We found 5 cases where GC analysis demon-
strated detectable propylene glycol (in one case as high as
147 mg/dL) following activated charcoal administration.
Although there have been many studies of the antidotal
properties of activated charcoal, no pharmacokinetic study
in humans has examined the OG that may be caused by
the propylene glycol excipient. A pharmacokinetic study
of activated charcoal has been performed on dogs showing
substantial increases in serum osmolality and lactate fol-
lowing administration of activated charcoal doses typical
of veterinary practice [51]. A study of the pharmacoki-
netics of activated charcoal in humans with respect to OG
and propylene glycol absorption would be of interest.
This study has several limitations. The first is that clini-
cal and laboratory practice for the medical center of this
study utilized OG (specifically greater than 14) as a major
factor in determining whether GC analysis was performed,
resulting in a potential work-up bias. In particular,
although GC analysis could be performed in the absence
of an elevated OG with pathology resident or attending
physician approval, the extra approval step could have
Figure 4 Sensitivity and specificity for osmolal gaps for
diagnosis of toxic alcohol ingestions. The analysis includes all
patients with OG of 9 or greater.
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number of patients identified as having ingested toxic alcohols at a particular OG. The bars below the horizontal line indicate number of
patients with a cause other than toxic alcohol ingestion at that particular OG. The plot in (A) shows all data for OG of 9 and above. The plot in
(B) focuses on data for OG 15 and above only.
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raises the possibility that toxic alcohol ingestions were
missed by clinical history and physical but may have been
detectable by GC analysis had it been performed. How-
ever, chart review was performed on all patients with OG
of 9 to 14 (comprising 510 patients that was in addition to
the 341 patients with OG greater than 14), which did not
reveal additional patients with clinical histories compatible
with toxic alcohol ingestion. This suggests that clinically
significant ingestions of toxic alcohols rarely present with-
out an elevated OG.
The second limitation is that interpretation of OG is
often made in the absence of a prior ‘baseline’ OG mea-
sured during a time when the patient is not ill or not
intoxicated. For example, an OG of +10 (within the refer-
ence range of many clinical laboratories) could be clini-
cally meaningful in a patient whose baseline OG (during
time of health) is -10. Further complicating interpretation
of OG is that reference ranges for OG vary across clinical
laboratories based on institutional practice and the for-
mula used to calculate OG. This can be an issue particu-
larly when patients are transferred from one hospital to
another.
The third limitation is that the study population includes
many patients who were transferred from other hospitals
in addition to patients who presented for initial diagnosis.
For example, for patients who have ingested ethylene gly-
col or methanol, an OG is seen early in ingestion while an
anion gap (and a declining OG) appears as the parent
compound is metabolized. Transfer patients can also pre-
sent a referral bias in that patients with toxic alcohol
ingestions may be preferentially transferred to tertiary care
centers as opposed to other patients presenting with other
causes of altered mental status.
Conclusions
Our study concurs with other investigations that show
that OG can be a useful diagnostic test in conjunction
with clinical history and physical examination. Clinicians
should be aware of the common causes of elevated OG
other than toxic alcohols such as alcoholic ketoacidosis,
renal failure, shock, and diabetic ketoacidosis, and recent
administration of mannitol. In addition, given the techni-
cal challenges of GC analysis, sensitive and specific rapid
screening tests (e.g., enzymatic assays) for ethylene glycol
and methanol would be useful.
Additional material
Additional file 1: Summary of laboratory findings in patients with
ethanol-related cause of elevated osmolal gap. Contains a
breakdown of the laboratory studies performed in patients with elevated
osmolal gap thought to be related to recent ethanol consumption.
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